Molecular mechanisms of left ventricular hypertrophy (LVH) in systemic hypertension (SH) - Possible therapeutic perspectives

Journal of the American Society of Hypertension

Volumn 5, Issue 6, 2011, Pages 449-455

  Cacciapuoti, Federico ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

calcineurin; fasudil; geldanamycin; integrins; Left ventricular hypertrophy (LVH); scutellarin; statins; systemic hypertension (SH); vasoactive peptides

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; FASUDIL; GELDANAMYCIN; GUANINE NUCLEOTIDE BINDING PROTEIN; HEAT SHOCK PROTEIN; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; INTEGRIN; LOSARTAN; NIFEDIPINE; OLMESARTAN; RAS PROTEIN; RHO FACTOR; ROSUVASTATIN; SCUTELLARIN; SPIRONOLACTONE; TELMISARTAN; UNINDEXED DRUG; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CHINESE MEDICINE; DIURETIC THERAPY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ENZYME ACTIVITY; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE HYPERTROPHY; HERBAL MEDICINE; HUMAN; HYPERTENSION; LOW DRUG DOSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TRADITIONAL MEDICINE;

ALDOSTERONE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BLOOD PRESSURE; COMORBIDITY; HEAT-SHOCK PROTEINS; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN;

EID: 81255160759     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2011.08.006     Document Type: Review

References (62)

1. P.A. Richey, and S.P. Brown Pathological versus physiological left ventricular hypertrophy: a review J Sports Sci 16 1998 129 141
2. T.J. Molloy, P.M. Okin, R.B. Devereux, and P. Kligfield Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product JACC 20 1992 1180 1186
3. M. Sokolow, and T.P. Lyon The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads Am Heart J 37 1949 161 186
4. D.W. Romhilt, and E.H. Estes Jr. A point score for the ECG diagnosis of left ventricular hypertrophy Am Heart J 75 1968 752 758
5. R.B. Devereux, D.R. Alonso, E.M. Lutas, G. Gottlieb, E. Campo, and I. Sachs Echocardiographic assessment of left ventricular hypertrophy: comparison to necroscopy findings Am J Cardiol 57 1986 450 458
6. P.N. Casale, R.B. Devereux, P. Kligfield, R.R. Eisenberg, D.H. Miller, and B.S. Chaudhory Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria JACC 6 1985 572 580
7. D. Levy, R.J. Garrison, D.D. Savage, W.B. Kannel, and W.P. Castelli Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study N Engl J Med 322 1990 1561 1566
8. K.M. Baker, G.W. Booz, and D.E. Dostal Cardiac actions of angiotensin II. Role of an intracardiac renin-angiotensin system Annu Rev Physiol 54 1992 227 241
9. G.W. Dorn, and J.H. Brown Gq signaling in cardiac adaptation and maladaptation Trends Cardiovasc Med 9 1999 26 34
10. H. Aoki, S. Izumo, and J. Sadoshima Angiotensin II activates RhoA cardiac myocytes: a critical role of RhoA in angiotensin II-induced premyofibril formation Circ Res 82 1998 666 676
11. V.P. Sah, M. Hoshijima, K.R. Chien, and J.H. Brown Rho is required for Galphaq and alpha-1-adrenergic receptor signaling in cardiomyocytes. Dissociation of Ras and Rho pathways J Biol Chem 271 1996 31185 31190
12. M. Harada, H. Itoh, O. Nakagawa, Y. Ogawa, Y. Miyamoto, and K. Kuwahara Significance of ventricular myocytes and nonmyocytes interaction during cardiocyte hypertrophy: evidence for endothelin-1 as a paracrine hypertrophic factor from cardiac nonmyocytes Circulation 96 1997 3737 3744
13. KB activation in angiotensin II-induced cardiac cell hypertrophy Exp Mol Med 42 2010 703 711
14. KB activation and chronic inflammation in angiotensin II-induced oxidative stress, hypertension and cardiac hypertrophy. Abstract 224, Canadian Cardiovascular Congress 2004, October 23-27, Calgary, Alberta.
15. KB activation is required for the development of cardiac hypertrophy in vivo Am J Physiol Heart Circ Physiol 287 2004 H1712 H1720
16. kB in Angiotensin II and Isoproterenol-induced cardiac hypertrophy in vivo Circulation 111 2005 2319 2325
17. S.G. Pereira, and F. Oakley Nuclear factor-kappaB1: regulation and function Int J Biochem Biol 40 2008 1425 1430
18. W.E. Stansfield, R.H. Tang, N.C. Moss, A.S. Baldwin, M.S. Willis, and C.H. Selzman Proteasome inhibition promotes regression of left ventricular hypertrophy Am J Physiol Heart J Physiol 294 2007 H645 H650
19. C. Barandier, X.F. Ming, and Z. Yang Small G proteins as a novel therapeutic targets in cardiovascular medicine News Physiol Sci 18 2003 18 22
20. A. Clerk, and P.H. Sugden Small guanine nucleotide-binding proteins and myocardial hypertrophy Circ Res 86 2000 1019 1023
21. P. Aspenstrom Effector for the Rho GPTases Curr Opin Cell Biol 11 1999 95 102
22. R. Ainawaka, I. Komuro, T. Yamazaki, Y. Zou, S. Kudoh, and W. Zhu Rho family small G proteins play a critical roles in mechanical stress-induced hypertrophic responses in cardiac myocytes Circ Res 84 1999 458-46
23. J.D. Molkentin, J.R. Lu, C.L. Antos, B. Markham, J. Richardson, and J. Robbins A calcineurin-dependent transcriptional pathway for cardiac hypertrophy Cell 93 1998 215 228
24. 2-Integrins contribute to skeletal muscle hypertrophy in mice Am J Physiol Cell Physiol 295 2008 C126 C136
25. P.M. Okin, R.B. Devereux, S. Jern, S.E. Kjeldsen, S. Julius, M.S. Nieminen LIFE Study Investigators Regression of electrocardiographic left ventricular hypertrophy during anti-hypertensive treatment and the prediction of major cardiovascular events JAMA 292 2004 2343 2349
26. B.D. de Graeff, and J.H. Reinders Dual effects of endothelin-1 on extracellular acidification by A725 smooth muscle cells Life Sci 60 1997 1399 1406
27. R.E. Schemieder, P. Martus, and A. Klingbell Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies JAMA 15 1996 1507 1513
28. B. Dalhof, K. Pennert, and L. Hansson Reversal of left hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies Am J Hypertens 5 1992 95 110
29. C.L. Curry, H. Robinson, R. Brown, J. Olivan, M. Sami, and G. Honos Regression of left ventricular hypertrophy in patients with essential hypertension: results of 6 month treatment with indapamide Am J Hypertens 8 1996 37S 40S
30. D. Galzerano, P. Tammaro, A. Cerciello, R. Breglio, M. Mallardo, and D. Lama Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study J Hum Hypertens 18 2004 53 59
31. 1 cyclins are involved in the mechanism of cardiac myocyte hypertrophy induced by angiotensin II Jpn Circ 64 2000 595 600
32. M. Bedin, A.M. Gaben, C. Saucier, and J. Mester Geldanamycin, an inhibitor of the chaperone activity of HSP90, induces MAPK-dependent cell cycle arrest Int J Cancer 109 2004 643 652
33. L. Van Aelst, and C. D'Souza Schotey RhoGTPases and signaling networks Gene Dev 11 1997 2295 2322
34. Y.X. Wang, V. de Cuntha, B.M. McNulty, J. Vincelette, W. Li, and D.F. Choy Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice Eur J Pharmacol 2-3 2005 215 222
35. H. Sheng, J. Zhu, X. Wu, and J. Zhang Blockade of calcineurin reverses cardiac hypertrophy and induces the downregulation of JNK mRNA expression in renovascular hypertensive rats JRAAS 9 2008 139 145
36. N. Jla, H. Okamoto, T. Shimizu, Y. Matsui, T. Sugawara, and M. Akino A newly developed angiotensin II antagonist CS 866, promotes regression of cardiac hypertrophy by reducing integrin beta1 expression Hypertens Res 26 2003 737 742
37. H. Kolke New pharmacologic aspects of CS866, the newest angiotensin II receptor antagonist J Cardiol 8 2001 33 36
38. M. Takemoto, K. Node, H. Nagakami, Y. Liao, M. Grimm, and Y. Takemoto Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy J Clin Invest 108 2001 1429 1437
39. S. Wassmann, U. Laufs, A.T. Baumer, K. Muller, C. Konkol, and H. Sauer Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GPTase Mol Pharmacol 59 2001 646 654
40. J.D. Luo, W.W. Zhang, G.P. Zhang, J.X. Guan, and X. Chen Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis Clin Exp Pharmacol Physiol 26 1999 903 908
41. U. Laufs, V. La Fata, J. Plutzky, and J.K. Liao Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors Circulation 97 1998 1129 1135
42. F. Simko Statins: a perspective for left ventricular hypertrophy treatment Eur J Clin Invest 37 2007 681 691
43. B.Y. Kang, and J.L. Mehta Rosuvastatin attenuates angiotensin-II-mediated cardiomyocyte hypertrophy via inhibition of LOX-1 J Cardiovasc Pharmacol Ther 14 2009 283 291
44. L.L. Lin, J.G. Liu, X.H. Yu, L.P. Qin, and D.F. Su Protective effects of scutellarin and breviscapine on brain and heart ischemia in rats J Cardiovasc Pharmacol 50 2007 327 332
45. 2+-mediated calcineurin and CaMKII signaling pathways Naunyn-Schmied Arch Pharmacol 381 2010 137 145
46. Z. Xiu, Z. Gao, D.Y. Huang, H.X. Li, L.N. Zhang, and Y.H. Lv Scutellarin promotes in vitro angiogenesis in human umbilical vein endothelial cells Bioc Biophysic Res Commun 400 2010 151 156
47. P. Carmeliet Angiogenesis in health and disease Nat Med 9 2003 653 660
48. K. Matsumura, K. Fujii, M. Oka, and M. Iida Role of aldosterone in left ventricular hypertrophy in hypertension Am J Hypertens 19 2006 13 18
49. F. Simko, J. Matuskova, I. Luptak, T. Pincikova, K. Krajcinomicova, and S. Sturtina Spironolactone differently influences remodeling of the left ventricle and aorta in L-NAME induced hypertension Physiol Res 56 2007 S25 S32
50. R. Rocha, and J.W. Funder The pathophysiology of aldosterone in the cardiovascular system Ann NY Acad Sci 970 2002 89 100
51. W. Qin, A.E. Rudolph, B.R. Bond, R. Rocha, E.A. Blomme, and J.J. Goellner Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure Circ Res 93 2003 69 76
52. A. Ouvrad-Pascaud, and F. Jaisser Pathophysiological role of the mineral corticoid receptor in heart: analysis of conditional transgenic models Pfugers Arch 445 2003 477 481
53. M. Rambausek, E. Ritz, G. Moll, O. Mehls, and H. Katus Myocardial hypertrophy in rats with renal insufficiency Kidney Int 28 1985 775 782
54. B. Dahlof, R.B. Devereux, S.E. Kjeldsen, S. Julius, G. Beevers, U. de Faire LIFE Study Group Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol Lancet 359 2002 995 1003
55. K. Amann, R. Neususs, E. Ritz, T. Irzyniec, G. Wiest, and G. Mall Changes in vascular architecture independent of blood pressure in experimental uremia Am J Hypertens 8 1995 409 417
56. C.G. Brilla, and K.T. Weber Reactive and reparative myocardial fibrosis in arterial hypertension in the rat Cardiovasc Res 26 1992 672 677
57. C. Savoia, R.M. Touyz, F. Amiri, and E.L. Schiffrin Selective mineral corticoid receptor blocker, eplerenone, reduces resistance artery stiffness in hypertensive patients Hypertension 51 2008 432 439
58. J. Mathew, P. Sleight, E. Lonn, D. Johnstone, J. Pogue, and Q. Yi Heart Outcomes Prevention Evaluation (HOPE) Investigators. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor, ramipril Circulation 104 2001 1615 1621
59. Pouleur AC, Uno H, Prescott MF, Desai A, Allelbaum E, Lukashevich V, et al. Suppression of Aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension. J Renin-Angiotensin-Aldactone Syst. doi:10.1177/1470320311414453.
60. R.B. Devereux, K. Wachtell, E. Gerdts, K. Boman, M.S. Nieminen, and V. Papadematriou Prognostic significance of left ventricular mass change during treatment of hypertension JAMA 292 2004 2350 2356
61. D. Piskorz, and A. Tommasi La hipertrofia ventricular izquierda no sempre revierte con el descenso de la presion arterial Insuf Cardiol 1 2010 11 16
62. M.L. Muiesan, M. Salvetti, D. Rizzoni, F. Donato, and E. Agabiti-Rosei Association of change in left ventricular mass with prognosis during long-term anti-hypertensive treatment J Hypertens 13 1995 1091 1095